Capital Asset Advisory Services LLC Grifols Sa Transaction History

Capital Asset Advisory Services LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 14, 2021	SELL	$14.07 - $17.3 $243,889 - $299,878	-17,334 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$16.62 - $18.94 $168,310 - $191,805	-10,127 Reduced 36.88%	17,334 $301,000
Q1 2021 May 13, 2021	BUY	$15.15 - $19.78 $58,448 - $76,311	3,858 Added 16.35%	27,461 $475,000
Q4 2020 Mar 02, 2021	BUY	$16.86 - $19.67 $155,415 - $181,318	9,218 Added 64.08%	23,603 $435,000
Q3 2020 Nov 18, 2020	SELL	$15.4 - $20.16 $4,096 - $5,362	-266 Reduced 1.82%	14,385 $249,000

Q2 2020 Aug 14, 2020	BUY	$18.24 - $21.45 $40,729 - $47,897	2,233 Added 17.98%	14,651 $264,000
Q1 2020 May 18, 2020	BUY	$16.28 - $25.63 $24,696 - $38,880	1,517 Added 13.92%	12,418 $243,000
Q4 2019 Feb 13, 2020	BUY	$19.57 - $23.52 $211,825 - $254,580	10,824 Added 14057.14%	10,901 $258,000
Q4 2019 Feb 12, 2020	BUY	$19.57 - $23.52 $1,506 - $1,811	77 New	77 $249,000

150

140M

3.54M

919K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $4.78B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Capital Asset Advisory Services LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Asset Advisory Services LLC with notifications on news.